DE69903716T2 - Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten - Google Patents

Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Info

Publication number
DE69903716T2
DE69903716T2 DE69903716T DE69903716T DE69903716T2 DE 69903716 T2 DE69903716 T2 DE 69903716T2 DE 69903716 T DE69903716 T DE 69903716T DE 69903716 T DE69903716 T DE 69903716T DE 69903716 T2 DE69903716 T2 DE 69903716T2
Authority
DE
Germany
Prior art keywords
combination
alpha
nicotinerge
gaba
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69903716T
Other languages
English (en)
Other versions
DE69903716D1 (de
Inventor
Gerard Raphael Dawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of DE69903716D1 publication Critical patent/DE69903716D1/de
Publication of DE69903716T2 publication Critical patent/DE69903716T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69903716T 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten Expired - Fee Related DE69903716T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805559.3A GB9805559D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
PCT/GB1999/000800 WO1999047142A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist

Publications (2)

Publication Number Publication Date
DE69903716D1 DE69903716D1 (de) 2002-12-05
DE69903716T2 true DE69903716T2 (de) 2003-08-14

Family

ID=10828630

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69903716T Expired - Fee Related DE69903716T2 (de) 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Country Status (9)

Country Link
EP (1) EP1061925B1 (de)
JP (1) JP2002506822A (de)
AT (1) ATE226823T1 (de)
AU (1) AU752013B2 (de)
CA (1) CA2324237A1 (de)
DE (1) DE69903716T2 (de)
ES (1) ES2185321T3 (de)
GB (1) GB9805559D0 (de)
WO (1) WO1999047142A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
EP0915877A1 (de) * 1996-07-25 1999-05-19 MERCK SHARP & DOHME LTD. Substituierte triazolo-pyridazinderivate als inverse agonisten des gaba-a alpha-5 rezeptor subtyps

Also Published As

Publication number Publication date
CA2324237A1 (en) 1999-09-23
EP1061925A1 (de) 2000-12-27
ATE226823T1 (de) 2002-11-15
JP2002506822A (ja) 2002-03-05
WO1999047142A1 (en) 1999-09-23
AU752013B2 (en) 2002-09-05
DE69903716D1 (de) 2002-12-05
EP1061925B1 (de) 2002-10-30
GB9805559D0 (en) 1998-05-13
AU2847799A (en) 1999-10-11
ES2185321T3 (es) 2003-04-16

Similar Documents

Publication Publication Date Title
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
DE69732868D1 (de) Mittel gegen Juckreiz
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
DE69934241D1 (de) Agonistische antikörper gegen tie2
DE59605568D1 (de) Benzonitrile als 5-HT Agonisten und Antagonisten
DK0951282T3 (da) Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
BG105256A (en) Muscarinic agonists and antagonists
DE69903716T2 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten
CO5460266A1 (es) Novedosos analogos de la somatostatina
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
EA199800858A1 (ru) Способ лечения насморка или аллергического ринита
BR9909868A (pt) Ascorbato de paroxetina
BR9909878A (pt) 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central
TR200100219T2 (tr) IL-8 Reseptörü Antagonistleri

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee